Cartesian Therapeutics' Approximately $104.8M Of Cash, Cash Equivalents, And Restricted Cash As Of March 31, 2024, Expected To Support Planned Operations Into 2H 2026
Cartesian Therapeutics' Approximately $104.8M Of Cash, Cash Equivalents, And Restricted Cash As Of March 31, 2024, Expected To Support Planned Operations Into 2H 2026
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.